Óscar Soto-Angona

Óscar Soto-Angona

Auto-generated profile, based on publicly available information

Óscar Soto-Angona

ANIMA Group, Institut de Recerca Sant Joan de Déu (IRSJD), Santa Rosa 39-57, 08950, Esplugues de Llobregat, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in BMC Medicine
Verified
Journal Article
Open access
PDF file
ÓSÓscar Soto-Angona
Óscar Soto-Angona
GAGerard Anmella
Gerard Anmella
MVMaría José Valdés-Florido
María José Valdés-Florido
NUNieves De Uribe-Viloria
Nieves De Uribe-Viloria
ACAndre F. Carvalho
Andre F. Carvalho
MBMichael Berk
Michael Berk
Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in over 5% of the parenchyma in the absence of excessive alcohol consumption. It is more prevalent in patients with diverse mental disorders, being part of the comorbidity driving loss of life expectancy and quality of life, yet remains a neglected entity. NAFLD can progress to non-alcoholic steatohepatitis (NASH) and increases the risk for cirrhosis and hepatic carcinoma. Both NAFLD and mental disorders share pathophysiological pathways, and also present a complex, bidirectional relationship with the metabolic syndrome (MetS) and related cardiometabolic diseases. Main text: This review compares the demographic data on NAFLD and NASH among the global population and the psychiatric population, finding differences that suggest a higher incidence of this disease among the latter. It also analyzes the link between NAFLD and psychiatric disorders, looking into common pathophysiological pathways, such as metabolic, genetic, and lifestyle factors. Finally, possible treatments, tailored approaches, and future research directions are suggested. Conclusion: NAFLD is part of a complex system of mental and non-communicable somatic disorders with a common pathogenesis, based on shared lifestyle and environmental risks, mediated by dysregulation of inflammation, oxidative stress pathways, and mitochondrial function. The recognition of the prevalent comorbidity between NAFLD and mental disorders is required to inform clinical practice and develop novel interventions to prevent and treat these complex and interacting disorders.

1 July 2021 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
GAGerard Anmella
Gerard Anmella
GFGiovanna Fico
Giovanna Fico
Mojtaba LotfalianyMojtaba Lotfaliany
Mojtaba Lotfaliany
DHDiego Hidalgo-Mazzei
Diego Hidalgo-Mazzei
ÓSÓscar Soto-Angona
Óscar Soto-Angona
MBMichael Berk
Michael Berk

1 June 2017 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
VMVicente Molina
Vicente Molina
ALAlba Lubeiro
Alba Lubeiro
OSOscar Soto
Oscar Soto
MRMargarita Rodriguez
Margarita Rodriguez
AÁAldara Álvarez
Aldara Álvarez
RLRodrigo de Luis-García
Rodrigo de Luis-García

1 January 2021 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Open access
PDF file
JVJúlia Vendrell-Serres
Júlia Vendrell-Serres
ÓSÓscar Soto-Angona
Óscar Soto-Angona
ARAmanda Rodríguez-Urrutia
Amanda Rodríguez-Urrutia
GAGara Arteaga-Henríquez
Gara Arteaga-Henríquez
JRJosep A. Ramos-Quiroga
Josep A. Ramos-Quiroga
Functional neurological disorder (FND) is a complex neuropsychiatric condition characterized by the presence of neurological symptoms and signs (either motor or sensory) that cannot be explained by any known medical or mental disease. It is frequently presented with psychiatric comorbidities, such as major depression. Its prognosis is poor, with low improvement or recovery rates at 1 year after their onset, and no particular treatment has demonstrated significant efficacy in this regard. Here, we describe the management of a patient affected by treatment-resistant depression (TRD) and FND characterized by mixed paralysis (sensory and motor) in the left arm, and who was successfully treated with esketamine nasal spray, achieving remission in both disorders. The US Food and Drug Administration and the European Medicines Agency recently approved esketamine, the S-enantiomer of ketamine, for treatment of TRD. It is a fast-acting drug that provides a rapid-onset improvement of depressive symptoms. We have presented the first case, to our knowledge, of functional neurological symptoms being successfully treated with esketamine in a patient with comorbid TRD. While the novelty of this data implies a clear need for further research, it is suggested that esketamine might be a useful tool for the treatment of FND, acting through different theorized mechanisms that are in tune with recent advances in knowledge of the etiopathology of FND.

21 November 2025 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
SMSantiago Madero
Santiago Madero
OSOscar Soto-Angona
Oscar Soto-Angona
GOGenis Ona
Genis Ona
JSJose Sánchez-Moreno
Jose Sánchez-Moreno
Eduard VietaEduard Vieta
Eduard Vieta
In this viewpoint, we explore the evolving landscape of psychedelic-assisted therapy in Europe, focusing on clinical, regulatory, and therapeutic developments. While access remains limited, recent initiatives in Switzerland, Germany, and the Czech Republic illustrate growing momentum toward regulated use. We examine the debate surrounding psychedelics as pharmacological agents versus psychotherapeutic catalysts and argue for an integrative framework that considers neurobiological mechanisms, subjective experience, and contextual factors. We focus on how their effects, particularly those involving neuroplasticity and critical periods, may interact with psychotherapeutic processes. We highlight the importance of context and psychological support in shaping outcomes and discuss the challenges of implementing scalable care models. Regulatory fragmentation and methodological complexities continue to hinder progress, but publicly funded trials such as EPIsoDE and PsyPal offer promising examples of ethical and effective approaches. In our view, the future of psychedelic therapy lies not in simplifying its complexity, but in embracing it.

24 June 2024 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
ÓSÓscar Soto-Angona
Óscar Soto-Angona
AFAdriana Fortea
Adriana Fortea
LFLydia Fortea
Lydia Fortea
MMMaría Martínez-Ramírez
María Martínez-Ramírez
ESEstevo Santamarina
Estevo Santamarina
GOGenís Ona
Genís Ona